Professor Magdalena Plebanksi is an internationally-recognised and award-winning researcher.
Her focus is on developing practical and affordable vaccines and treatments for complex diseases like malaria and cancer. She has also pioneered the use of synthetic size-defined non-inflammatory nanoparticles in vaccines.
Magdalena has forged a stellar career in medical and health research. She came to Australia from Oxford University in the UK, where she showed new ways in which malaria parasites can trick the human immune system. More recently, her insights have been used to help understand cancer progression across multiple human clinical trials, particularly leukemia and ovarian cancer.
Her nanoparticle studies also opened the door to new nanotechnology applications to prevent allergic airways disease. She has more than 50 patents in 10 patent families, which have supported the formation of biotechnology companies.
Magdalena has published more than 150 peer-reviewed full-length papers, including in leading journals such as Lancet, Nature, Science, Immunity, Nature Biotechnology, Nature Medicine and Nature Communications among others, and has secured funding from national and international grant bodies, as well as charitable and commercial funding.
- Solace2 Translational sub-study (administered by Australia New Zealand Gynaecological Oncology Group). Funded by: Australia New Zealand Gynaecological Oncology Group from (2019 to 2024)
- Innovative immune-based therapies and diagnostics: using nanotechnology for personalized medicine. Funded by: NHMRC Research Fellowships from (2019 to 2023)
- Preventing type 1 diabetes progression via a tolerance inducing vaccine (Administered by Victoria University). Funded by: ARC Special Research Initiatives via other University Grant (2014 onwards) from (2019 to 2021)
- VITAL: Vaccine immunomodulation throughout the ageing lifespan. Funded by: NHMRC Project Grants 2018 from (2018 to 2022)
- A randomised controlled trial of NMDA antagonist, memantine, for the treatment of borderline personality disorder (administered by Monash). Funded by: 044-National Health and Medical Research Council (NHMRC) Project Grants 2017 from (2018 to 2019)